Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

By V. Vogel, J. Costantino, D. Wickerham, W. Cronin, R. Cecchini, J. Atkins, T. Bevers, L. Fehrenbacher, E. Pajon, J. Wade and 11 more. Journal of the American Medical Association (JAMA), 2006

1,648 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/502944516fe1e8ec65aa59141c24f11f8dcec3bb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Victor G. Vogel
2. M. Akram
3. Mehwish Iqbal
4. J. Costantino
5. M. Daniyal
6. D. Wickerham
7. A. U. Khan
8. W. Cronin

Citations in the corpus

• Exemestane for breast-cancer prevention in postmenopausal women. (2011, neutral): “Back 106 77 21 2 306 (9) 119 80 23 222 (10) 0.”
• Awareness and current knowledge of breast cancer (2017, methodology): “Four big prospective studies have investigated the efficacy of tamoxifen versus placebo for breast cancer danger decline for females at elevated danger of breast cancer [189].”
• Update of the National Surgical Adjvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer (2010, positive): “The details of the trial methodology, including the definition of endpoints and the methods used for randomization, schedule of patient follow-up, patient testing, and trial monitoring, are described in the initial report of 2006, for which the data were cut off as of December 31, 2005 (9).”